Clinical Trials Logo

MEK Mutation clinical trials

View clinical trials related to MEK Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06326411 Recruiting - Melanoma Clinical Trials

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

NST-628
Start date: April 9, 2024
Phase: Phase 1
Study type: Interventional

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

NCT ID: NCT04985604 Recruiting - Colorectal Cancer Clinical Trials

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Start date: July 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key proteins of the RAS/RAF/MEK/ERK pathway, referred to as the MAPK pathway.